Saturday, September 30, 2023
Saturday, September 30, 2023

Contact us 561.316.3330

Jupiter Medical Center Earns National Recognition for Orthopedics: Earns 5 Highly Coveted Accreditations by BC BS Association

Jupiter Medical Center, ranked number one for safety, quality and patient satisfaction in Palm Beach County and the Treasure Coast region, today announced it has been selected as a Blue Distinction Center+ for Total Hip & Knee Replacement, and Spine Surgery, as well as receiving The Gold Seal of Approval® from The Joint Commission for Total Hip & Knee Replacement, Total Shoulder Replacement, and Spine Surgery.

Jupiter Medical Center is the only hospital in the state of Florida to earn all five highly coveted accreditations, a designation awarded by the Blue Cross and Blue Shield Association for delivering exceptional care and results for patients undergoing these orthopedic surgeries.

The orthopedic program at Jupiter Medical Center provides world-class care to patients who come from all parts of the country to receive the best outcomes possible,” said Dr. Amit Rastogi, president and CEO of Jupiter Medical Center. “It’s an honor to be recognized for meeting the vigorous criteria for outstanding orthopedic care set by both the prestigious The Joint Commission and the Blue Distinction Specialty Care program.”

The Joint Commission is the recognized global leader for health care accreditation. The independent, not-for-profit organization examines a hospital’s quality achievement in patient care and safety and establishes the most rigorous standards to raise the bar among health care providers globally. Furthermore, Blue Distinction Centers® are nationally designated healthcare facilities that demonstrate a commitment to delivering high-quality patient safety and better health outcomes, based on objective measures that were developed with input from the medical community and leading accreditation and quality organizations.

Jupiter Medical Center takes a coordinated and comprehensive approach to orthopedic care, delivered by an expert, multidisciplinary team of surgeons, physical therapists and other skilled clinicians. The Anderson Family Orthopedic & Spine Center at Jupiter Medical Center has long been at the forefront of joint replacement and spine care, providing innovative and high-quality diagnosis and treatment.

As a Blue Distinction Center for Knee and Hip Replacement, Jupiter Medical Center is recognized for its expertise in total knee and hip replacement surgeries, including assessments of patients’ physical abilities after surgery, known as “functional outcomes.” Blue Distinction Centers+ is an additional designation recognizing Jupiter Medical Center’s performance on measures of cost-effectiveness and affordability, such as lower complication rates and fewer hospital readmissions.

Jupiter Medical Center has also invested in innovative technologies that offer less invasive treatment options, better results, and speedier recovery times. The hospital recently enhanced its total knee replacement capabilities with Mako Robotic-Arm Assisted Technology. The Mako Robotic-Arm creates a 3D virtual model of the patient’s bone anatomy, allowing medical teams to place implants virtually, prior to surgery. Once the surgical team is satisfied with the virtual model, they can use the Mako to proceed with surgery. This allows for more precise bone preparation, less soft tissue injury, and the potential for less pain and a speedier recovery. The Mako is also used for partial knee and hip replacements, and total hip replacements.

“Implementing new technologies, such as the Mako for knee and hip replacements, is just one example of our ongoing efforts to enhance patient care and help our patients get back to enjoying their lives without pain or mobility limitations,” Dr. Rastogi said.

Facilities designated as Blue Distinction Centers® for Spine Surgery demonstrate expertise in cervical and lumbar fusion, cervical laminectomy and lumbar laminectomy/discectomy procedures, resulting in fewer patient complications and readmissions compared to other facilities. Additionally, to meet The Joint Commission’s certification for spine surgery, providers must meet three core requirements: standards, clinical practice guidelines, and performance measurement.

Dr. Rastogi says, “To be the only hospital in the state to earn all of these highly coveted awards for quality and safety, is an accomplishment earned by the expertise of the entire orthopedic team, and our focus on minimally invasive techniques and reducing patient recovery times.”

Jupiter Medical Center

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy